Big Drop Bounce Plays

[voidy]

NXXI 52 week low

Nutrition 21, Inc. Announces Successful Transition to OTC Bulletin Board
Date : 10/23/2009 @ 12:49PM
Source : PR Newswire
Stock : (NXXI)
Quote : 0.0525 -0.0175 (-25.00%) @ 8:18AM




Nutrition 21, Inc. Announces Successful Transition to OTC Bulletin Board

PURCHASE, N.Y. , Oct. 23 /PRNewswire-FirstCall/ -- Nutrition 21, Inc. (OTC Bulletin Board: NXXI), the developer and marketer of nutritional supplements under the Iceland Health®, Chromax® and Diabetes Essentials® brands that help consumers manage blood sugar levels, improve cardiovascular health, enhance memory and reduce chronic joint pain, announced today that on October 20, 2009 the listing of its common stock on the NASDAQ Capital Market was successfully transferred to listing on the OTC Bulletin Board under the symbol NXXI.OB.

About Nutrition 21

Nutrition 21, Inc., headquartered in Purchase, NY, is a nutritional bioscience company and the maker of chromium picolinate-based and omega-3 fish oil-based supplements with health benefits substantiated by clinical research. Nutrition 21 holds more than 30 patents for nutrition products and uses. Nutrition 21's portfolio of health and wellness products include: Iceland Health Chromax, Iceland Health Advanced Memory Formula(TM), Iceland Health Omega-3 Fish Oil, Iceland Health Joint Relief, and Diabetes Essentials® The company also manufactures private label supplements and ingredients for third parties. Nutrition 21 distributes its products nationally through more than 30,000 major food, drug and super center stores throughout the United States and internationally. For more information please visit http://www.nutrition21.com/.

Safe Harbor Provision

This press release may contain certain forward-looking statements. The words "believe," "expect," "anticipate" and other similar expressions generally identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based largely on the company's current expectations and are subject to a number of risks and uncertainties, including without limitation: the effect of the expiration of patents; regulatory issues; uncertainty in the outcomes of clinical trials; changes in external market factors; changes in the company's business or growth strategy or an inability to execute its strategy due to changes in its industry or the economy generally; the emergence of new or growing competitors; various other competitive factors; and other risks and uncertainties indicated from time to time in the company's filings with the Securities and Exchange Commission, including its Form 10-K for the year ended June 30, 2009. Actual results could differ materially from the results referred to in the forward-looking statements. In light of these risks and uncertainties, there can be no assurance that the results referred to in the forward-looking statements contained in this press release will in fact occur. Additionally, the company makes no commitment to disclose any revisions to forward-looking statements, or any facts, events or circumstances after the date hereof that may bear upon forward-looking statements.

Contact: Nutrition 21, Inc. Lytham Partners, LLC Alan Kirschbaum Joe Diaz [phone] [phone]

DATASOURCE: Nutrition 21, Inc.

CONTACT: Alan Kirschbaum of Nutrition 21, Inc., [phone]; or Joe

Diaz of Lytham Partners, LLC, [phone], for Nutrition 21, Inc.

Web Site: http://www.nutrition21.com/